ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. 15th November 2012 - 2:23 pm
ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the 2012 Annual American College of Rheumatology (“ACR”) Meeting which is being held between 11 – 14 of November. ImmuPharma will be presenting on Wednesday 14 November 2012. The ACR Annual Scientific Meeting is the premier scientific meeting devoted to rheumatic diseases.
ImmuPharma recently had confirmation that the ACR Abstract Selection Committee had accepted ImmuPharma’s abstract paper on the Company’s final clinical data for its LupuzorTM Phase IIb trial. LupuzorTM is ImmuPharma’s potential blockbuster drug for Lupus, a chronic autoimmune disease. LupuzorTM has received Special Protocol Assessment and Fast Track Designation from the FDA for a Phase III trial. The title of the session is called “Systemic Lupus Erythematosus – Clinical Aspects and Treatment”.
The presentation will be given by the authors of the abstract: ImmuPharma’s President and Chief Scientific Officer, Dr. Robert Zimmer, together with Pr. Daniel J. Wallace, Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles, and a leading practitioner within the field of Lupus, and Prof. Sylviane Muller, Research Director at CNRS, Strasbourg, France and the key inventor of LupuzorTM. (Full biographies can be found in ‘Notes to Editors’.)
Analyst meeting: Friday 16 November at 10am
Venue: Buchanan, 107 Cheapside, London EC2V 6DN
Following the presentation at the ACR conference on 14th November, ImmuPharma will host an analyst meeting on Friday 16 November in London to provide full disclosure of the abstract paper and clinical analysis of the Lupuzor Phase IIb study. The presentation will be given by Dr Robert Zimmer and ImmuPharma’s CEO, Dimitri Dimitriou. Please contact Lisa Baderoon, Head of Investor Relations, if you would like to attend (email@example.com